🔎 Trials Near Me

Home › Acute Myeloid Leukemia › Texas › Houston

Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Houston, TX

Isang pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Houston. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 2/3
  • The University of Texas MD Anderson Cancer Center /ID# 279402, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07581002

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • UT MD Anderson Cancer Center, Houston
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Nagre-recruitObservasyonal na pag-aaral
  • Texas Children's Hospital, Houston
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06131801

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Nagre-recruitPhase 1
  • University of Texas MD Anderson Cancer Center, Houston
Edad 12 hanggang 78 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT03802695

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Nagre-recruitPhase 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 3
  • Houston Methodist Cancer Center, Houston
  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Nagre-recruitPhase 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05564390

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

Nagre-recruitPhase 2
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT03629171

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Nagre-recruitPhase 1/2
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06548230

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Nagre-recruitPhase 3
  • Clinical Trial Site, Houston
Edad 12 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07211958

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Nagre-recruitPhase 1/2
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT03661307

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
  • M D Anderson Cancer Center, Houston
Edad 12 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT05360160

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Nagre-recruitPhase 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06317649

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • The University of Texas M. D. Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06769490

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Nagre-recruitPhase 1/2
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT03214562

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Nagre-recruitPhase 1/2
  • MD Anderson Cancer Center, Houston
Edad 12 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06284486

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Nagre-recruitPhase 1
  • M D Anderson Cancer Center, Houston
Edad 1 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT03630991

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

Nagre-recruitPhase 1
  • MD Anderson, Houston
Edad 12 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06786533

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Nagre-recruitPhase 3
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

Nagre-recruitPhase 1
  • Texas Children's Hospital, Houston
  • The Methodist Hospital, Houston
Hanggang edad 75 · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06345027

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Nagre-recruitPhase 2
  • The Methodist Hospital Research Institute, Houston
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06824168

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Nagre-recruitPhase 2
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04996875

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Nagre-recruitPhase 1/2
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT03471260

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Nagre-recruitPhase 2
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT03683433

A Study of BGB-11417 in Participants With Myeloid Malignancies

Nagre-recruitPhase 1/2
  • Md Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT04771130

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Nagre-recruitPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06616636

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 1/2
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06969430

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Nagre-recruitPhase 1/2
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT05010122

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Nagre-recruitPhase 2
  • M D Anderson Cancer Center, Houston
Edad 12 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT03383575

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 2 hanggang 18 · Lahat ng kasarian · Na-update Set 4, 2026 · NCT06191978

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Nagre-recruitPhase 1/2
  • MD Anderson, Houston
Edad 12 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT04588922

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Nagre-recruitPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT06834282

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Nagre-recruitPhase 2
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04493164

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06533761

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Nagre-recruitPhase 2
  • The University of Texas M. D. Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06811233

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Nagre-recruitPhase 1/2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 3
  • Texas Children's Hospital, Houston
29 Days – 21 Years · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05183035

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Nagre-recruitMaagang Phase 1
  • Texas Children's Cancer and Hematology Center, Houston
1 Month – 30 Years · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT07059975

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Nagre-recruitPhase 3
  • University of Texas, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Nagre-recruitPhase 2/3Malugod na tinatanggap ang malusog na boluntaryo
  • M D Anderson Cancer Center, Houston
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT04708054

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06285890

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Nagre-recruitPhase 1/2
  • M D Anderson Cancer Center, Houston
Edad 12 hanggang 80 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT05092451

Personalized NK Cell Therapy in CBT

Nagre-recruitPhase 2
  • M D Anderson Cancer Center, Houston
Edad 15 hanggang 80 · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT02727803

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Nagre-recruitPhase 1/2
  • Research Site, Houston
Edad 16 pataas · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT07155226

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Nagre-recruitPhase 1
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT05010772

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Nagre-recruitPhase 2
  • University of Texas MD Anderson Cancer Center, Houston
Edad 60 pataas · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT01515527

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Nagre-recruitObservasyonal na pag-aaral
  • M.D. Anderson Cancer Center, Houston
  • Texas Children's Hospital - Baylor Medical Center, Houston
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

A Study of Revumenib and Mezigdomide in People With Leukemia

Nagre-recruitPhase 1/2
  • MD Anderson Cancer Center (Data Collection Only), Houston
Edad 12 pataas · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT07356154

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT03113643

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 15, 2026 · NCT05768932

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 15, 2026 · NCT02074839

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 3 hanggang 21 · Lahat ng kasarian · Na-update Hun 12, 2026 · NCT06448013

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Nagre-recruitPhase 1/2
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 12, 2026 · NCT04047641

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Nagre-recruitPhase 1
  • M.D. Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 12, 2026 · NCT05834244

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Nagre-recruitPhase 2
  • M D Anderson Cancer Center, Houston
Edad 50 pataas · Lahat ng kasarian · Na-update Hun 8, 2026 · NCT03586609

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Nagre-recruitPhase 1
  • MD Anderson, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update May 28, 2026 · NCT04953897

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Nagre-recruitPhase 1
  • MD Anderson, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update May 28, 2026 · NCT04953910

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Nagre-recruitPhase 2
  • M D Anderson Cancer Center, Houston
Edad 12 pataas · Lahat ng kasarian · Na-update May 22, 2026 · NCT03589729

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Nagre-recruitPhase 2
  • M D Anderson Cancer Center, Houston
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update May 20, 2026 · NCT02115295

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Nagre-recruitPhase 1/2
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update May 20, 2026 · NCT04774393

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 13 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT04771572

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Nagre-recruitPhase 2/3
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 30, 2026 · NCT04256317

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 17, 2026 · NCT02390635

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Nagre-recruitPhase 1/2
  • M D Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 16, 2026 · NCT04140487

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Nagre-recruitPhase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT05732103

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 25, 2026 · NCT07107126

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Nagre-recruitPhase 1/2
  • MDACC, Houston
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 24, 2026 · NCT04988555

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Nagre-recruitPhase 2
  • MD Anderson, Houston
Edad 18 hanggang 66 · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06859424

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 16, 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 9, 2026 · NCT06950034

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Nagre-recruitPhase 1
  • MD Anderson, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 16, 2026 · NCT05143996

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Nagre-recruitPhase 1/2
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT06680752

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
  • M.D. Anderson Cancer Center, Department of Leukemia, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2025 · NCT05986240

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 31, 2025 · NCT06549790

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Nagre-recruitPhase 1/2
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2025 · NCT05211570

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Nagre-recruitPhase 1
  • The University of Texas M.D. Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2025 · NCT06501196

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update May 11, 2025 · NCT06634394

Study of REM-422 in Patients With AML or Higher Risk MDS

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 23, 2025 · NCT06297941

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • MD Anderson Cancer Centre, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 10, 2025 · NCT06613217

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 10, 2025 · NCT05190471

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Nagre-recruitPhase 2
  • University of Texas M.D. Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 7, 2025 · NCT02781883

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Nagre-recruitPhase 1
  • MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 15, 2024 · NCT06034275

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Nagre-recruitPhase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2024 · NCT04243785

Pag-aaral para sa Acute Myeloid Leukemia sa ibang lungsod

Iba pang pag-aaral sa Houston

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.